{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:38:16Z","timestamp":1791599896242,"version":"4.3.4"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s43440-026-00852-8","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:22:56Z","timestamp":1775546576000},"page":"641-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sigma receptor ligands in selected affective disorders, psychoses, and addictions \u2013 a narrative review"],"prefix":"10.1007","volume":"78","author":[{"given":"Agnieszka","family":"Piechal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Jakimiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Pyrzanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"9","key":"852_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.tips.2019.07.006","volume":"40","author":"HR Schmidt","year":"2019","unstructured":"Schmidt HR, Kruse AC. The Molecular Function of \u03c3 Receptors: Past, Present, and Future. Trends Pharmacol Sci. 2019;40(9):636\u201354. https:\/\/doi.org\/10.1016\/j.tips.2019.07.006.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"852_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/157015905774322516","volume":"3","author":"T Hayashi","year":"2005","unstructured":"Hayashi T, Su TP. The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology. Curr Neuropharmacol. 2005;3(4):267\u201380. https:\/\/doi.org\/10.2174\/157015905774322516.","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"852_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3109\/10799893.2015.1015737","volume":"36","author":"CG Rousseaux","year":"2016","unstructured":"Rousseaux CG, Greene SF. Sigma receptors [\u03c3Rs]: biology in normal and diseased states. J Recept Signal Transduct Res. 2016;36(4):327\u201388. https:\/\/doi.org\/10.3109\/10799893.2015.1015737.","journal-title":"J Recept Signal Transduct Res"},{"key":"852_CR4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fnins.2019.00862","volume":"28","author":"DA Ryskamp","year":"2019","unstructured":"Ryskamp DA, Korban S, Zhemkov V, Kraskovskaya N, Bezprozvanny I. Neuronal Sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases. Front Neurosci. 2019a;28:13:862. https:\/\/doi.org\/10.3389\/fnins.2019.00862. eCollection 2019.","journal-title":"Front Neurosci"},{"key":"852_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fncel.2018.00314","volume":"12","author":"J Jia","year":"2018","unstructured":"Jia J, Cheng J, Wang C, Zhen X. Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases. Front Cell Neurosci. 2018;12:314. https:\/\/doi.org\/10.3389\/fncel.2018.00314.","journal-title":"Front Cell Neurosci"},{"issue":"11","key":"852_CR6","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.4103\/1673-5374.259609","volume":"14","author":"K Terada","year":"2019","unstructured":"Terada K, Migita K, Matsushima Y, Kamei C. Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders. Neural Regen Res. 2019;14(11):1893\u20134. https:\/\/doi.org\/10.4103\/1673-5374.259609.","journal-title":"Neural Regen Res"},{"issue":"15","key":"852_CR7","doi-asserted-by":"publisher","first-page":"8072","DOI":"10.1073\/pnas.93.15.8072","volume":"93","author":"M Hanner","year":"1996","unstructured":"Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA. 1996;93(15):8072\u20137. https:\/\/doi.org\/10.1073\/pnas.93.15.8072.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"852_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.tips.2016.01.003","volume":"37","author":"TP Su","year":"2016","unstructured":"Su TP, Su TC, Nakamura Y, Tsai SY. The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends Pharmacol Sci. 2016;37(4):262\u201378. https:\/\/doi.org\/10.1016\/j.tips.2016.01.003.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"852_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0922-4106(94)90115-5","volume":"268","author":"SB Hellewell","year":"1994","unstructured":"Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: Characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol. 1994;268(1):9\u201318. https:\/\/doi.org\/10.1016\/0922-4106(94)90115-5.","journal-title":"Eur J Pharmacol"},{"key":"852_CR10","doi-asserted-by":"publisher","unstructured":"Hong VM, Rade AD, Yan SM, Bhaskara A, Yousuf MS, Chen M, et al. Loss of Sigma-2 Receptor\/TMEM97 is associated with neuropathic injury-induced depression-like behaviors in female mice. eNeuro. 2024;11(7):ENEURO.0488-23.2024. https:\/\/doi.org\/10.1523\/ENEURO.0488-23.2024.","DOI":"10.1523\/ENEURO.0488-23.2024"},{"issue":"5916","key":"852_CR11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1126\/science.1166127","volume":"323","author":"D Fontanilla","year":"2009","unstructured":"Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323(5916):934\u20137. https:\/\/doi.org\/10.1126\/science.1166127.","journal-title":"Science"},{"issue":"1","key":"852_CR12","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1038\/s41467-024-49894-7","volume":"15","author":"C Fu","year":"2024","unstructured":"Fu C, Xiao Y, Zhou X, Sun Z. Insight into binding of endogenous neurosteroid ligands to the sigma-1 receptor. Nat Commun. 2024;15(1):5619. https:\/\/doi.org\/10.1038\/s41467-024-49894-7.","journal-title":"Nat Commun"},{"issue":"6","key":"852_CR13","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1007\/s43440-021-00310-7","volume":"73","author":"A Piechal","year":"2021","unstructured":"Piechal A, Jakimiuk A, Mirowska-Guzel D. Sigma receptors and neurological disorders. Pharmacol Rep. 2021;73(6):1582\u201394. https:\/\/doi.org\/10.1007\/s43440-021-00310-7.","journal-title":"Pharmacol Rep"},{"key":"852_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2014.01.064","volume":"727","author":"T Ishima","year":"2014","unstructured":"Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167\u201373. https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.064.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"852_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4155\/fmc.10.279","volume":"3","author":"S Narayanan","year":"2011","unstructured":"Narayanan S, Bhat R, Mesangeau C, Poupaert JH, McCurdy CR. Early development of sigma-receptor ligands. Future Med Chem. 2011;3(1):79\u201394. https:\/\/doi.org\/10.4155\/fmc.10.279.","journal-title":"Future Med Chem"},{"issue":"D1","key":"852_CR16","doi-asserted-by":"publisher","first-page":"D1446","DOI":"10.1093\/nar\/gkaf1067","volume":"54","author":"SD Harding","year":"2026","unstructured":"Harding SD, Armstrong JF, Faccenda E, Southan C, Alexander SPH, Davenport AP, Spedding M, Davies JA. The IUPHAR\/BPS Guide to PHARMACOLOGY in 2026. Nucleic Acids Res. 2026;54(D1):D1446\u201356. https:\/\/doi.org\/10.1093\/nar\/gkaf1067.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"852_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/hup.1106","volume":"25","author":"I Hindmarch","year":"2010","unstructured":"Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010;25(3):193\u2013200. https:\/\/doi.org\/10.1002\/hup.1106.","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"852_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2174\/157015908787386113","volume":"6","author":"EJ Cobos","year":"2008","unstructured":"Cobos EJ, Entrena JM, Nieto FR, Cend\u00e1n CM, Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol. 2008;6(4):344\u201366. https:\/\/doi.org\/10.2174\/157015908787386113.","journal-title":"Curr Neuropharmacol"},{"key":"852_CR19","doi-asserted-by":"publisher","first-page":"106771","DOI":"10.1016\/j.phrs.2023.106771","volume":"191","author":"E Vavers","year":"2023","unstructured":"Vavers E, Zvejniece L, Dambrova M. Sigma-1 receptor and seizures. Pharmacol Res. 2023;191:106771. https:\/\/doi.org\/10.1016\/j.phrs.2023.106771.","journal-title":"Pharmacol Res"},{"issue":"4","key":"852_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.euroneuro.2011.08.002","volume":"22","author":"MJ Robson","year":"2012","unstructured":"Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR. Evaluation of sigma (\u03c3) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol. 2012;22(4):308\u201317. https:\/\/doi.org\/10.1016\/j.euroneuro.2011.08.002.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"852_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0269881120959644","volume":"35","author":"LA Jelen","year":"2021","unstructured":"Jelen LA, Young AH, Stone JM, Ketamine. A tale of two enantiomers. J Psychopharmacol. 2021;35(2):109\u201323. https:\/\/doi.org\/10.1177\/0269881120959644.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"852_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70(3):621\u201360. https:\/\/doi.org\/10.1124\/pr.117.015198.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"852_CR23","doi-asserted-by":"publisher","first-page":"e89985","DOI":"10.1371\/journal.pone.0089985","volume":"28","author":"L Nguyen","year":"2014","unstructured":"Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS ONE. 2014;28(2):e89985.","journal-title":"PLoS ONE"},{"issue":"4","key":"852_CR24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41401-023-01201-8","volume":"45","author":"H Ma","year":"2024","unstructured":"Ma H, Li JF, Qiao X, Zhang Y, Hou XJ, Chang HX, et al. Sigma-1 receptor activation mediates the sustained antidepressant effect of ketamine in mice via increasing BDNF levels. Acta Pharmacol Sin. 2024;45(4):704\u201313. https:\/\/doi.org\/10.1038\/s41401-023-01201-8.","journal-title":"Acta Pharmacol Sin"},{"issue":"13","key":"852_CR25","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1097\/00001756-200109170-00043","volume":"12","author":"AJ Law","year":"2001","unstructured":"Law AJ, Deakin JF. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. NeuroReport. 2001;12(13):2971\u20134.","journal-title":"NeuroReport"},{"key":"852_CR26","doi-asserted-by":"crossref","unstructured":"Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double blind controlled trial. Am J Psychiatry. 2022;179(7):4909. NCT03595579 (ASCEND), 2018.","DOI":"10.1176\/appi.ajp.21080800"},{"key":"852_CR27","unstructured":"COMET Study Group. NCT04039022 (COMET). An open-label study to assess the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder. 2019. ClinicalTrials.gov identifier: NCT04039022."},{"key":"852_CR28","unstructured":"NCT04608396 (MERIT). A Randomized, Double-blind, Placebo-controlled Study of AXS-05 for Relapse Prevention in Treatment Resistant Depression, 2020."},{"key":"852_CR29","unstructured":"Randomized NCTA. Double-blind, active-controlled study of AXS-05 for the prevention of relapse of depressive symptoms, 2023."},{"key":"852_CR30","unstructured":"STRIDE-1 Study Group. NCT02741791 (STRIDE-1). Randomized, double-blind, active-controlled trial to assess the efficacy and safety of AXS-05 administered orally to subjects with treatment-resistant major depressive disorder. 2016. ClinicalTrials.gov identifier: NCT02741791."},{"key":"852_CR31","unstructured":"EVOLVE Study Group. NCT04634669 (EVOLVE). An open-label study to assess the long-term safety and efficacy of AXS-05 in subjects with treatment-resistant depression. 2020. ClinicalTrials.gov identifier: NCT04634669."},{"key":"852_CR32","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/S0924-977X(99)80011-X","volume":"9","author":"AC Pande","year":"1999","unstructured":"Pande AC, Gen\u00e8ve J, Scherrer B, Smith F, Leadbetter RA, de Meynard C. A placebo-controlled trial of igmesine in the treatment of major depression. Eur Neuropsychopharmacol. 1999;9:S138. https:\/\/doi.org\/10.1016\/S0924-977X(99)80011-X.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"852_CR33","doi-asserted-by":"publisher","first-page":"9580","DOI":"10.3390\/ijms24119580","volume":"24","author":"MV Voronin","year":"2023","unstructured":"Voronin MV, Shangin SV, Litvinova SA, Abramova EV, Kurbanov RD, Rybina IV, et al. Pharmacological Analysis of GABAA Receptor and Sigma1R Chaperone Interaction: Research Report I\u2015Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABAA Receptors\u2019 Ligands. Int J Mol Sci. 2023;24(11):9580. https:\/\/doi.org\/10.3390\/ijms24119580.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"852_CR34","doi-asserted-by":"publisher","first-page":"5618","DOI":"10.1073\/pnas.81.17.5618","volume":"81","author":"SW Tam","year":"1984","unstructured":"Tam SW, Cook L. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3 H] SKF 10,047 and [3H] haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA. 1984;81(17):5618\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"852_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0028-3908(95)00193-X","volume":"35","author":"S Okuyama","year":"1996","unstructured":"Okuyama S, Imagawa Y, Tomisawa K. Behavioral Evidence for Modulation by Sigma Ligands of (+) MK-801-induced Hyperlocomotion in Monoamine-depleted Mice. Neuropharmacology. 1996;35(4):467\u201374.","journal-title":"Neuropharmacology"},{"issue":"5","key":"852_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/1874241600902010007","volume":"2","author":"T Ishima","year":"2009","unstructured":"Ishima T, Fujita Y, Kohno M, Kunitachi S, Horio M, Takatsu Y, et al. Improvement of phencyclidine induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J. 2009;2(5):7\u201311.","journal-title":"Open Clin Chem J"},{"key":"852_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.brainres.2009.05.004","volume":"1279","author":"S Kunitachi","year":"2009","unstructured":"Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibushi Y, et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res. 2009;1279:189\u201396.","journal-title":"Brain Res"},{"issue":"3","key":"852_CR38","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1176\/ajp.153.3.414","volume":"153","author":"F Gatti","year":"1996","unstructured":"Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry. 1996;153(3):414\u20136. https:\/\/doi.org\/10.1176\/ajp.153.3.414.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"852_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ddr.430160109","volume":"16","author":"MR Munetz","year":"1989","unstructured":"Munetz MR, Schulz SC, Bellin M, Harty I. Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia. Drug Devel Res. 1989;16(1):79\u201383. https:\/\/doi.org\/10.1002\/ddr.430160109.","journal-title":"Drug Devel Res"},{"key":"852_CR40","first-page":"103","volume":"27","author":"RL Borison","year":"1991","unstructured":"Borison RL, Diamond BI, Dren AT. Does sigma receptor antagonism predict clinical antipsychotic efficacy? Psychopharmacol Bull. 1991;27:103\u20136.","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"852_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/JCP.0000000000000850","volume":"38","author":"A Haji Seyed Javadi","year":"2018","unstructured":"Haji Seyed Javadi A, Shafikhani AA, Zamir SM, Khanshir ZF. Evaluation of the Effect of Fluvoxamine in Patients With Schizophrenia Under Risperidone Treatment: A Clinical Trial. J Clin Psychopharmacol. 2018;38(2):119\u201324. https:\/\/doi.org\/10.1097\/JCP.0000000000000850.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"852_CR42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/JCP","volume":"40","author":"W Zheng","year":"2020","unstructured":"Zheng W, Xiang YQ, Cai DB, Yang XH, Zhang L, Zheng W, et al. Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials. J Clin Psychopharmacol. 2020;40(4):386\u201390. https:\/\/doi.org\/10.1097\/JCP.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"852_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/ph17020166","volume":"17","author":"FA Ludwig","year":"2024","unstructured":"Ludwig FA, Laurini E, Schmidt J, Pricl S, Deuther-Conrad W, W\u00fcnsch B. [18F] Fluspidine-A PET Tracer for Imaging of \u03c31 Receptors in the Central Nervous System. Pharmaceuticals (Basel). 2024;17(2):166. https:\/\/doi.org\/10.3390\/ph17020166.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"852_CR44","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.neulet.2007.04.055","volume":"420","author":"A Dhir","year":"2007","unstructured":"Dhir A, Kulkarni SK. Involvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine. Neurosci Lett. 2007;420(3):204\u20138.","journal-title":"Neurosci Lett"},{"issue":"4","key":"852_CR45","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1472-8206.2008.00605.x","volume":"22","author":"A Dhir","year":"2008","unstructured":"Dhir A, Kulkarni SK. Possible involvement of sigma-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor. Fundam Clin Pharmacol. 2008;22(4):387\u201394.","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"852_CR46","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s12035-014-8923-2","volume":"52","author":"S Moriguchi","year":"2015","unstructured":"Moriguchi S, Sakagami H, Yabuki Y, Sasaki Y, Izumi H, Zhang C, et al. Stimulation of Sigma-1 Receptor Ameliorates Depressive-like Behaviors in CaMKIV Null Mice. Mol Neurobiol. 2015;52(3):1210\u201322. https:\/\/doi.org\/10.1007\/s12035-014-8923-2.","journal-title":"Mol Neurobiol"},{"issue":"1\u20133","key":"852_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0014-2999(96)00201-4","volume":"306","author":"K Matsuno","year":"1996","unstructured":"Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol. 1996;306(1\u20133):271\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"852_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0091-3057(98)00093-8","volume":"61","author":"M Ukai","year":"1998","unstructured":"Ukai M, Maeda H, Nanya Y, Kameyama T, Matsuno K. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav. 1998;61(3):247\u201352.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"852_CR49","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0022-3565(24)29502-1","volume":"298","author":"A Urani","year":"2001","unstructured":"Urani A, Roman FJ, Phan VL, Su TP, Maurice T. The antidepressant-like effect induced by sigma (1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther. 2001;298(3):1269\u201379.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"852_CR50","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/00008877-200211000-00003","volume":"13","author":"G Skuza","year":"2002","unstructured":"Skuza G, Rogoz Z. A potential antidepressant activity of SA4503, a selective 1 receptor agonist. Behav Pharmacol. 2002;13(7):537\u201343.","journal-title":"Behav Pharmacol"},{"issue":"8","key":"852_CR51","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S0028-3908(01)00147-2","volume":"41","author":"K Tottori","year":"2001","unstructured":"Tottori K, Miwa T, Uwahodo Y, Yamada S, Nakai M, Oshiro Y, et al. Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC14523. Neuropharmacology. 2001;41(8):976\u201388.","journal-title":"Neuropharmacology"},{"key":"852_CR52","doi-asserted-by":"publisher","first-page":"9251","DOI":"10.1038\/s41598-020-65849-6","volume":"10","author":"JM Brimson","year":"2020","unstructured":"Brimson JM, Akula KK, Abbas H, Ferry DR, Kulkarni SK, Russel ST, et al. Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression. Sci Rep. 2020;10:9251. https:\/\/doi.org\/10.1038\/s41598-020-65849-6.","journal-title":"Sci Rep"},{"key":"852_CR53","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0006-8993(98)00797-5","volume":"807","author":"X Liang","year":"1998","unstructured":"Liang X, Wang RY. Biphasic modulatory action of the selective sigma receptor ligand SR 31742A on N-methyl-D-aspartate-induced neuronal responses in the frontal cortex. Brain Res. 1998;807:208\u201313.","journal-title":"Brain Res"},{"key":"852_CR54","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.neubiorev.2015.03.005","volume":"52","author":"F Freudenberg","year":"2015","unstructured":"Freudenberg F, Celikel T, Reif A. The role of \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity? Neurosci Biobehav Rev. 2015;52:193\u2013206. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.03.005.","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"852_CR55","first-page":"699","volume":"54","author":"G Skuza","year":"2002","unstructured":"Skuza G, Rog\u00f3z Z. Effect of combined treatment with selective sigma ligands and amantadine in the forced swimming test in rats. Pol J Pharmacol. 2002;54(6):699\u2013702.","journal-title":"Pol J Pharmacol"},{"issue":"2","key":"852_CR56","first-page":"217","volume":"57","author":"G Skuza","year":"2006","unstructured":"Skuza G, Rog\u00f3z Z. The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats. J Physiol Pharmacol. 2006;57(2):217\u201329.","journal-title":"J Physiol Pharmacol"},{"key":"852_CR57","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.neuropharm.2017.01.014","volume":"116","author":"B Zhang","year":"2017","unstructured":"Zhang B, Wang L, Chen T, Hong J, Sha S, Wang J, et al. Sigma-1 Receptor Deficiency Reduces GABAergic Inhibition in the Basolateral Amygdala Leading to LTD Impairment and Depressive-like Behaviors. Neuropharmacology. 2017;116:387\u201398. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.01.014.","journal-title":"Neuropharmacology"},{"issue":"1","key":"852_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00213-002-1150-y","volume":"163","author":"A Urani","year":"2002","unstructured":"Urani A, Romieu P, Portales-Casamar E, Roman FJ, Maurice T. The Antidepressant-like Effect Induced by the Sigma (1) (Sigma (1)) Receptor Agonist Igmesine Involves Modulation of Intracellular Calcium Mobilization. Psychopharmacol Berl. 2002;163(1):26\u201335. https:\/\/doi.org\/10.1007\/s00213-002-1150-y.","journal-title":"Psychopharmacol Berl"},{"issue":"3","key":"852_CR59","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1124\/jpet.102.041970","volume":"303","author":"M Takebayashi","year":"2002","unstructured":"Takebayashi M, Hayashi T, Su TP. Nerve growth factor induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J Pharmacol Exp Ther. 2002;303(3):1227\u201337.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"852_CR60","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jphs.2024.02.003","volume":"154","author":"P Ren","year":"2024","unstructured":"Ren P, Wang JY, Chen HL, Wang Y, Cui LY, Duan JY, et al. Activation of \u03c3-1 receptor mitigates estrogen withdrawal-induced anxiety\/depressive-like behavior in mice via restoration of GABA\/glutamate signaling and neuroplasticity in the hippocampus. J Pharmacol Sci. 2024;154(4):236\u201345. https:\/\/doi.org\/10.1016\/j.jphs.2024.02.003.","journal-title":"J Pharmacol Sci"},{"key":"852_CR61","doi-asserted-by":"publisher","first-page":"105937","DOI":"10.1016\/j.neuint.2025.105937","volume":"184","author":"P Ren","year":"2025","unstructured":"Ren P, Wang JY, Xu MJ, Chen HL, Duan JY, Li YF. Sigma-1 receptor activation produces faster antidepressant-like effect through enhancement of hippocampal neuroplasticity: focus on sigma-1-5-HT1A heteroreceptor complex. Neurochem. Int. 2025;184:105937. https:\/\/doi.org\/10.1016\/j.neuint.2025.105937.","journal-title":"Int"},{"issue":"5","key":"852_CR62","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/cns.12502","volume":"22","author":"Y Wang","year":"2016","unstructured":"Wang Y, Guo L, Jiang HF, Zheng LT, Zhang A, Zhen XC. Allosteric Modulation of Sigma-1 Receptors Elicits Rapid Antidepressant Activity. CNS Neurosci Ther. 2016;22(5):368\u201377. https:\/\/doi.org\/10.1111\/cns.12502.","journal-title":"CNS Neurosci Ther"},{"key":"852_CR63","doi-asserted-by":"publisher","first-page":"105390","DOI":"10.1016\/j.neuint.2022.105390","volume":"159","author":"Y-M Wang","year":"2022","unstructured":"Wang Y-M, Xia C-Y, Jia H-M, He J, Lian W-W, Yan Y, et al. Sigma-1 receptor: A potential target for the development of antidepressants. Neurochem Int. 2022;159:105390. https:\/\/doi.org\/10.1016\/j.neuint.2022.105390.","journal-title":"Neurochem Int"},{"key":"852_CR64","unstructured":"NCT00551109. SA4503 8-Week study in major Depressive Disorder (MDD), 2007."},{"key":"852_CR65","doi-asserted-by":"publisher","first-page":"175647","DOI":"10.1016\/j.ejphar.2023.175647","volume":"946","author":"P Ren","year":"2023","unstructured":"Ren P, Wang J, Chen L, Chang H, Zeng Z, Li G, et al. Sigma-1 receptor agonist properties that mediate the fast-onset antidepressant effect of hypidone hydrochloride (YL-0919). Eur J Pharmacol. 2023;946:175647. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175647.","journal-title":"Eur J Pharmacol"},{"issue":"478","key":"852_CR66","doi-asserted-by":"publisher","first-page":"eaau5266","DOI":"10.1126\/scitranslmed.aau5266","volume":"6","author":"DA Rosen","year":"2019","unstructured":"Rosen DA, Seki SM, Fern\u00e1ndez-Casta\u00f1eda A, Beiter RM, Eccles JD, Woodfolk JA, et al. Modulation of the sigma-1 receptor-IRE1 pathway is benefcial in preclinical models of infammation and sepsis. Sci Transl Med. 2019;6(478):eaau5266.","journal-title":"Sci Transl Med"},{"issue":"10","key":"852_CR67","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/ijnp\/pyy049","volume":"21","author":"P S\u00e1nchez-Bl\u00e1zquez","year":"2018","unstructured":"S\u00e1nchez-Bl\u00e1zquez P, Cort\u00e9s-Montero E, Rodr\u00edguez-Mu\u00f1oz M, Garz\u00f3n J. Sigma 1 Receptor Antagonists Inhibit Manic-Like Behaviors in Two Congenital Strains of Mice. Int J Neuropsychopharmacol. 2018;21(10):938\u201348. https:\/\/doi.org\/10.1093\/ijnp\/pyy049.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"852_CR68","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4103\/0253-7176.150852","volume":"37","author":"K Firoz","year":"2015","unstructured":"Firoz K, Khaleel A, Rajmohan V, Kumar M, Raghuram T. Mania induced by opipramol. Indian J Psychol Med. 2015;37(1):96\u20138. https:\/\/doi.org\/10.4103\/0253-7176.150852.","journal-title":"Indian J Psychol Med"},{"issue":"1\u20133","key":"852_CR69","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0014-2999(95)00830-6","volume":"299","author":"H Kamei","year":"1996","unstructured":"Kamei H, Kameyama T, Nabeshima T. (+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress through the activation of phenytoin-regulated sigma 1 sites. Eur J Pharmacol. 1996;299(1\u20133):21\u20138.","journal-title":"Eur J Pharmacol"},{"issue":"2\u20133","key":"852_CR70","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s0014-2999(96)00851-5","volume":"29","author":"H Kamei","year":"1997","unstructured":"Kamei H, Noda Y, Kameyama T, Nabeshima T. Role of (+)-SKF-10,047-sensitive sub-population of sigma 1 receptors in amelioration of conditioned fear stress in rats: association with mesolimbic dopaminergic systems. Eur J Pharmacol. 1997;29(2\u20133):165\u201372. https:\/\/doi.org\/10.1016\/s0014-2999(96)00851-5.","journal-title":"Eur J Pharmacol"},{"key":"852_CR71","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0893-133X(00)00103-2","volume":"23","author":"Y Noda","year":"2000","unstructured":"Noda Y, Kamei H, Kamei Y, Nagai T, Nishida M, Nabeshima T. Neurosteroids ameliorate conditioned fear stress: an association with sigma1 receptors. Neuropsychopharmacology. 2000;23:276\u201384.","journal-title":"Neuropsychopharmacology"},{"key":"852_CR72","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejphar.2003.12.018","volume":"486","author":"A Urani","year":"2004","unstructured":"Urani A, Romieu P, Roman FJ, Yamada K, Noda Y, Kamei H, et al. Enhanced antidepressant efficacy of sigma 1 receptor agonists in rats after chronic intracerebroventricular infusion of -amyloid-(1\u201340) protein. Eur J Pharmacol. 2004;486:151\u201361.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"852_CR73","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.3892\/mmr.2017.7185","volume":"16","author":"LL Ji","year":"2017","unstructured":"Ji LL, Peng JB, Fu CH, Tong L, Wang ZY. Sigma-1 receptor activation ameliorates anxiety-like behavior through NR2A-CREB-BDNF signaling pathway in a rat model submitted to single-prolonged stress. Mol Med Rep. 2017;16(4):4987\u201393.","journal-title":"Mol Med Rep"},{"issue":"11","key":"852_CR74","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.3390\/ijms22115455","volume":"22","author":"MV Voronin","year":"2021","unstructured":"Voronin MV, Vakhitova YV, Tsypysheva IP, Tsypyshev DO, Rybina IV, Kurbanov RD, et al. Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole. Int J Mol Sci. 2021;22(11):5455. https:\/\/doi.org\/10.3390\/ijms22115455.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"852_CR75","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1038\/npp.2012.89","volume":"37","author":"P Cottone","year":"2012","unstructured":"Cottone P, Wang X, Park JW, Valenza M, Blasio A, Kwak J, et al. Antagonism of sigma-1 receptors blocks compulsive-like eating. Neuropsychopharmacology. 2012;37(12):2593\u2013604. https:\/\/doi.org\/10.1038\/npp.2012.89.","journal-title":"Neuropsychopharmacology"},{"key":"852_CR76","doi-asserted-by":"publisher","first-page":"172796","DOI":"10.1016\/j.pbb.2019.172796","volume":"187","author":"WE Kaufmann","year":"2019","unstructured":"Kaufmann WE, Sprouse J, Rebowe N, Hanania T, Klamer D, Missling CU. ANAVEX\u00ae2\u201373 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome. Pharmacol Biochem Behav. 2019;187:172796. https:\/\/doi.org\/10.1016\/j.pbb.2019.172796.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"852_CR77","first-page":"266","volume":"2","author":"C Heading","year":"2001","unstructured":"Heading C, Siramesine H, Lundbeck. Curr Opin Investig Drugs. 2001;2(2):266\u201370.","journal-title":"Curr Opin Investig Drugs"},{"issue":"9","key":"852_CR78","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/070674379303800910","volume":"38","author":"AK Malla","year":"1993","unstructured":"Malla AK, Norman RM, Williamson P. Stability of positive and negative symptoms in schizophrenia. Can J Psychiatry. 1993;38(9):617\u201321.","journal-title":"Can J Psychiatry"},{"issue":"3","key":"852_CR79","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1527-3458.1998.tb00065.x","volume":"4","author":"X Guitart","year":"1998","unstructured":"Guitart X, Codony X, Ballar\u00edn M, Dordal A, Farr\u00e9 AJ. E-5842: a new potent and preferential sigma ligand: preclinical pharmacological profile. CNS Drug Rev. 1998;4(3):201\u201324.","journal-title":"CNS Drug Rev"},{"issue":"2\u20133","key":"852_CR80","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0014-2999(93)90059-Q","volume":"23","author":"NG R\u00fcckert","year":"1993","unstructured":"R\u00fcckert NG, Schmidt WJ. The sigma receptor ligand 1,3-di- (2-tolyl) guanidine in animal models of schizophrenia. Eur J Pharmacol. 1993;23(2\u20133):261\u20137.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"852_CR81","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s002130051061","volume":"145","author":"S Takahashi","year":"1999","unstructured":"Takahashi S, Sonehara K, Takagi K, Miwa T, Horikomi K, Mita N, et al. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors. Psychopharmacology. 1999;145(3):295\u2013302.","journal-title":"Psychopharmacology"},{"issue":"5","key":"852_CR82","first-page":"626","volume":"58","author":"G Skuza","year":"2006","unstructured":"Skuza G, Rogoz Z. Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity. Pharmacol Rep. 2006;58(5):626\u201335.","journal-title":"Pharmacol Rep"},{"issue":"2","key":"852_CR83","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0014-2999(95)00693-1","volume":"296","author":"H Ujike","year":"1996","unstructured":"Ujike H, Kuroda S, Otsuki S. Sigma receptor antagonists block the development of sensitization to cocaine. Eur J Pharmacol. 1996;296(2):123\u20138.","journal-title":"Eur J Pharmacol"},{"key":"852_CR84","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s11064-019-02873-7","volume":"44","author":"L Wang","year":"2019","unstructured":"Wang L, Zhang Y, Wang C, Zhang X, Wang Z, Liang X, et al. A natural product with high afnity to sigma and 5-HT7 receptors as novel therapeutic drug for negative and cognitive symptoms of schizophrenia. Neurochem Res. 2019;44:2536\u201345. https:\/\/doi.org\/10.1007\/s11064-019-02873-7.","journal-title":"Neurochem Res"},{"issue":"18","key":"852_CR85","doi-asserted-by":"publisher","first-page":"PL285","DOI":"10.1016\/0024-3205(93)90588-T","volume":"53","author":"S Okuyama","year":"1993","unstructured":"Okuyama S, Imagawa Y, Ogawa S, Araki H, Ajima A, Tanaka M, et al. NE-100: a novel sigma receptor antagonist: in-vivo tests. Life Sci. 1993;53(18):PL285\u201390.","journal-title":"Life Sci"},{"key":"852_CR86","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/schbul\/sbab137","volume":"48","author":"J Chen","year":"2022","unstructured":"Chen J, Li G, Qin P, Chen J, Ye N, Waddington JL, et al. Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects. Schizophr Bull. 2022;48:474\u201384. https:\/\/doi.org\/10.1093\/schbul\/sbab137.","journal-title":"Schizophr Bull"},{"key":"852_CR87","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/0024-3205(86)90640-5","volume":"38","author":"RM Ferris","year":"1986","unstructured":"Ferris RM, Tang FL, Chang KJ, Russell A. Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain. Life Sci. 1986;38:2329\u201337.","journal-title":"Life Sci"},{"key":"852_CR88","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1021\/jm9902943","volume":"42","author":"SM Husbands","year":"1999","unstructured":"Husbands SM, Izenwasser S, Kopajtic T, Bowen WD, Vilner BJ, Katz J, et al. Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl) propyl] carbazole (rimcazole) analogues. J Med Chem. 1999;42:4446\u201355.","journal-title":"J Med Chem"},{"key":"852_CR89","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/BF00427460","volume":"84","author":"G Chouinard","year":"1984","unstructured":"Chouinard G, Annable L. An early Phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology. 1984;84:282\u20134. https:\/\/doi.org\/10.1007\/BF00427460.","journal-title":"Psychopharmacology"},{"key":"852_CR90","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/ddr.430050412","volume":"5","author":"G Schwarcz","year":"1985","unstructured":"Schwarcz G, Halaris A, Dren A, Manberg P. Open label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenics. Drug Dev Res. 1985;5:387\u201393. https:\/\/doi.org\/10.1002\/ddr.430050412.","journal-title":"Drug Dev Res"},{"key":"852_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1527-3458.2004.tb00001.x","volume":"10","author":"DL Gilmore","year":"2004","unstructured":"Gilmore DL, Liu Y, Matsumoto RR. Review of the pharmacological and clinical profile of rimcazole. CNS Drug Rev. 2004;10:1\u201322.","journal-title":"CNS Drug Rev"},{"key":"852_CR92","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s002130050323","volume":"132","author":"RM Frieboes","year":"1997","unstructured":"Frieboes RM, Murck H, Wiedemann K, Holsboer F, Steiger A. Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. Psychopharmacology. 1997;132:82\u20138. https:\/\/doi.org\/10.1007\/s002130050323.","journal-title":"Psychopharmacology"},{"key":"852_CR93","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1055\/s-2007-979194","volume":"32","author":"MT Huber","year":"1999","unstructured":"Huber MT, Gotthardt U, Schreiber W, Krieg JC. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial. Pharmacopsychiatry. 1999;32:68\u201372. https:\/\/doi.org\/10.1055\/s-2007-979194.","journal-title":"Pharmacopsychiatry"},{"key":"852_CR94","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/s0165-1781(99)00100-6","volume":"89","author":"MJ M\u00fcller","year":"1999","unstructured":"M\u00fcller MJ, Grunder G, Wetzel H, M\u00fcller-Siecheneder F, Marx-Dannigkeit P, Benkert O, et al. Antipsychotic effects, and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Res. 1999;89:275\u201380. https:\/\/doi.org\/10.1016\/s0165-1781(99)00100-6.","journal-title":"Psychiatry Res"},{"key":"852_CR95","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/npp.1994.5","volume":"10","author":"GR Gewirtz","year":"1994","unstructured":"Gewirtz GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, et al. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology. 1994;10:37\u201340. https:\/\/doi.org\/10.1038\/npp.1994.5.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"852_CR96","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","volume":"174","author":"M Davidson","year":"2017","unstructured":"Davidson M, Saoud J, Staner C, Noel N, Luthringer E, Werner S, et al. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017;174(12):1195\u2013202. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17010122.","journal-title":"Am J Psychiatry"},{"key":"852_CR97","doi-asserted-by":"publisher","unstructured":"Davidson M, Saoud J, Staner C, Noel N, Werner S, Luthringer E, et al. Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia. Schizophr Bull. 2022;48(3):609\u2009\u2013\u200919. https:\/\/doi.org\/10.1093\/schbul\/sbac013. NCT 03397134, 2017.","DOI":"10.1093\/schbul\/sbac013"},{"key":"852_CR98","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1527-3458.1996.tb00299.x","volume":"2","author":"S Okuyama","year":"1996","unstructured":"Okuyama S, Nakazato A. NE-100: a novel sigma receptor antagonist. CNS Drug Rev. 1996;2:226\u201337.","journal-title":"CNS Drug Rev"},{"key":"852_CR99","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0014-2999(00)00430-1","volume":"401","author":"RR Matsumoto","year":"2000","unstructured":"Matsumoto RR, Pouw B. Correlation between neuroleptic binding to 1 and 2 receptors and acute dystonic reactions. Eur J Pharmacol. 2000;401:155\u201360.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"852_CR100","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2174\/138161212799436601","volume":"18","author":"MJ Robson","year":"2012","unstructured":"Robson MJ, Noorbakhsh B, Seminerio MJ, Matsumoto RR. Sigma-1 receptors: potential targets for the treatment of substance abuse. Curr Pharm Des. 2012;18(7):902\u201319.","journal-title":"Curr Pharm Des"},{"issue":"1\u20133","key":"852_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0014-2999(03)01723-0","volume":"469","author":"RR Matsumoto","year":"2003","unstructured":"Matsumoto RR, Liu Y, Lerner M, Howard EC, Brackett DJ. Sigma receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol. 2003;469(1\u20133):1\u201312.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"852_CR102","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.neuropharm.2005.04.016","volume":"49","author":"EC Nguyen","year":"2005","unstructured":"Nguyen EC, McCracken KA, Liu Y, Pouw B, Matsumoto RR. Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology. 2005;49(5):638\u201345.","journal-title":"Neuropharmacology"},{"issue":"14","key":"852_CR103","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.1984.03350140035021","volume":"252","author":"RE Mittleman","year":"1984","unstructured":"Mittleman RE, Wetli CV. Death caused by recreational cocaine use: an update. J Am Med Assoc. 1984;252(14):1889\u201393.","journal-title":"J Am Med Assoc"},{"issue":"4","key":"852_CR104","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0893-133X(01)00391-8","volume":"26","author":"P Romieu","year":"2002","unstructured":"Romieu P, Phan VL, Martin-Fardon R, Maurice T. Involvement of the receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology. 2002;26(4):444\u201355.","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"852_CR105","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1523\/JNEUROSCI.23-09-03572.2003","volume":"23","author":"P Romieu","year":"2003","unstructured":"Romieu P, Martin-Fardon R, Bowen WD, Maurice T. Sigma 1 receptor-related neuroactive steroids modulate cocaine-induced reward. J Neurosci. 2003;23(9):3572\u20136.","journal-title":"J Neurosci"},{"issue":"13","key":"852_CR106","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1097\/00001756-200009110-00011","volume":"11","author":"P Romieu","year":"2000","unstructured":"Romieu P, Martin-Fardon R, Maurice T. Involvement of the receptor in the cocaine-induced conditioned place preference. NeuroReport. 2000;11(13):2885\u20138.","journal-title":"NeuroReport"},{"issue":"4","key":"852_CR107","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0091-3057(03)00002-9","volume":"74","author":"T Maurice","year":"2003","unstructured":"Maurice T, Casalino M, Lacroix M, Romieu P. Involvement of the sigma 1 receptor in the motivational effects of ethanol in mice. Pharmacol Biochem Behav. 2003;74(4):869\u201376.","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"852_CR108","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1046\/j.1460-9568.2003.02950.x","volume":"18","author":"F Langa","year":"2003","unstructured":"Langa F, Codony X, Tovar V, Lavado A, Gim\u00e9nez E, Cozar P, et al. Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. Eur J Neurosci. 2003;18(8):2188\u201396.","journal-title":"Eur J Neurosci"},{"key":"852_CR109","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0014-2999(99)00113-2","volume":"370","author":"KA McCracken","year":"1999","unstructured":"McCracken KA, Bowen WD, de Costa BR, Matsumoto RR. Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur J Pharmacol. 1999;370:225\u201332.","journal-title":"Eur J Pharmacol"},{"issue":"1\u20132","key":"852_CR110","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1016\/S0014-2999(01)00891-3","volume":"417","author":"RR Matsumoto","year":"2001","unstructured":"Matsumoto RR, Mack AL. (+\/-)-SM 21 attenuates the convulsive and locomotor stimulatory effects of cocaine in mice. Eur J Pharmacol. 2001;417(1\u20132):R1\u20132.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"852_CR111","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.euroneuro.2008.07.006","volume":"8","author":"RR Matsumoto","year":"2008","unstructured":"Matsumoto RR, Shaikh J, Wilson LL, Vedam S, Coop A. Attenuation of methamphetamine-induced effects through the antagonism of sigma (\u03c3) receptors: Evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol. 2008;8(12):871\u201381.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1\u20133","key":"852_CR112","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejphar.2006.09.038","volume":"53","author":"MK Brammer","year":"2006","unstructured":"Brammer MK, Gilmore DL, Matsumoto RR. Interactions between 3,4-methylenedioxymethamphetamine and 1 receptors. Eur J Pharmacol. 2006;53(1\u20133):141\u20135.","journal-title":"Eur J Pharmacol"},{"issue":"2\u20133","key":"852_CR113","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0014-2999(01)00968-2","volume":"419","author":"RR Matsumoto","year":"2001","unstructured":"Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting receptors produce anti-cocaine effects in mice. Eur J Pharmacol. 2001a;419(2\u20133):163\u201374.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"852_CR114","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0014-2999(00)00917-1","volume":"411","author":"RR Matsumoto","year":"2001","unstructured":"Matsumoto RR, McCracken KA, Pouw B, Miller J, Bowen WD, Williams W, et al. N-alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice. Eur J Pharmacol. 2001b;411(3):261\u201373.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"852_CR115","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejphar.2004.03.037","volume":"492","author":"RR Matsumoto","year":"2004","unstructured":"Matsumoto RR, Gilmore DL, Pouw B, Bowen WD, Williams W, Kausar A, et al. Novel analogs of the sigma receptor ligand BD1008 attenuate cocaine-induced toxicity in mice. Eur J Pharmacol. 2004a;492(1):21\u20136.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"852_CR116","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.pbb.2004.01.014","volume":"77","author":"RR Matsumoto","year":"2004","unstructured":"Matsumoto RR, Potelleret FH, Mack A, Pouw B, Zhang Y, Bowen WD. Structure-activity comparison of YZ-069, a novel sigma ligand, and four analogs in receptor binding and behavioral studies. Pharmacol Biochem Behav. 2004b;77(4):775\u201381.","journal-title":"Pharmacol Biochem Behav"},{"issue":"7","key":"852_CR117","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0028-3908(01)00116-2","volume":"41","author":"RR Matsumoto","year":"2001","unstructured":"Matsumoto RR, Hewett KL, Pouw B, Bowen WD, Husbands SM, Cao JJ, et al. Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology. 2001c;41(7):878\u201386.","journal-title":"Neuropharmacology"},{"issue":"8","key":"852_CR118","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0028-3908(02)00056-4","volume":"42","author":"RR Matsumoto","year":"2002","unstructured":"Matsumoto RR, McCracken KA, Pouw B, Zhang Y, Bowen WD. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology. 2002;42(8):1043\u201355.","journal-title":"Neuropharmacology"},{"issue":"6","key":"852_CR119","doi-asserted-by":"publisher","first-page":"PL31","DOI":"10.1016\/0024-3205(92)90415-L","volume":"51","author":"H Ujike","year":"1992","unstructured":"Ujike H, Tsuchida K, Akiyama K, Otsuki S. Supersensitivity of sigma receptors after repeated administration of cocaine. Life Sci. 1992;51(6):PL31\u20136.","journal-title":"Life Sci"},{"issue":"1\u20132","key":"852_CR120","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1016\/S0014-2999(01)01229-8","volume":"426","author":"B Horan","year":"2001","unstructured":"Horan B, Gardner EL, Dewey SL, Brodie JD, Ashby CR. The selective \u03c31 receptor agonist, 1-(3,4-dimethoxyphenethyl)-4- (phenylpropyl)piperazine (SA4503), blocks the acquisition of the conditioned place preference response to (\u2013)-nicotine in rats. Eur J Pharmacol. 2001;426(1\u20132):R1\u20132.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"852_CR121","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00213-009-1548-x","volume":"205","author":"V Sabino","year":"2009","unstructured":"Sabino V, Cottone P, Zhao Y, Steardo L Jr, Koob GF, Zorrilla EP. Selective reduction of alcohol drinking in Sardinian alcohol preferring rats by a sigma-1 receptor antagonist. Psychopharmacology. 2009a;205(2):327\u201335.","journal-title":"Psychopharmacology"},{"issue":"6","key":"852_CR122","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/npp.2008.192","volume":"34","author":"V Sabino","year":"2009","unstructured":"Sabino V, Cottone P, Zhao Y, Iyer MR, Steardo L Jr, Steardo L, et al. The sigma-receptor antagonist BD1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology. 2009b;34(6):1482\u201393.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"852_CR123","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/acer.14635","volume":"45","author":"SG Quadir","year":"2021","unstructured":"Quadir SG, Tanino SM, Sami YN, Minnig MA, Iyer MR, Rice KC, et al. Antagonism of Sigma-1 receptor blocks heavy alcohol drinking and associated hyperalgesia in male mice. Alcohol Clin Exp Res. 2021;45(7):1398\u2013407. https:\/\/doi.org\/10.1111\/acer.14635.","journal-title":"Alcohol Clin Exp Res"},{"key":"852_CR124","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13041-018-0395-2","volume":"11","author":"M Rodr\u00edguez-Mu\u00f1oz","year":"2018","unstructured":"Rodr\u00edguez-Mu\u00f1oz M, S\u00e1nchez-Bl\u00e1zquez P, Herrero-Labrador R, Mart\u00ednez-Murillo R, Merlos M, Garz\u00f3n J. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma-1 receptor. Mol Brain. 2018;11:51. https:\/\/doi.org\/10.1186\/s13041-018-0395-2.","journal-title":"Mol Brain"},{"issue":"11","key":"852_CR125","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1167\/iovs.08-1867","volume":"49","author":"KT Tchedre","year":"2008","unstructured":"Tchedre KT, Huang RQ, Dibas A, Krishnamoorthy RR, Dillon GH, Yorio T. Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest Ophthalmol Vis Sci. 2008;49(11):4993\u20135002. https:\/\/doi.org\/10.1167\/iovs.08-1867.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"26","key":"852_CR126","doi-asserted-by":"publisher","first-page":"18387","DOI":"10.1074\/jbc.274.26.18387","volume":"274","author":"RA Wilke","year":"1999","unstructured":"Wilke RA, Mehta RP, Lupardus PJ, Chen Y, Ruoho AE, Jackson MB. Sigma receptor photolabeling and sigma receptor-mediated modulation of potassium channels in tumor cells. J Biol Chem. 1999;274(26):18387\u201392. https:\/\/doi.org\/10.1074\/jbc.274.26.18387.","journal-title":"J Biol Chem"},{"issue":"44","key":"852_CR127","doi-asserted-by":"publisher","first-page":"37021","DOI":"10.1074\/jbc.M112.382077","volume":"287","author":"D Balasuriya","year":"2012","unstructured":"Balasuriya D, Stewart AP, Crottes D, Borgese F, Soriani O, Edwardson JM. The Sigma-1 Receptor Binds to the Nav1.5 Voltage-gated Na+ Channel with 4-Fold Symmetry. J Biol Chem. 2012;287(44):37021\u20139.","journal-title":"J Biol Chem"},{"issue":"46","key":"852_CR128","doi-asserted-by":"publisher","first-page":"18219","DOI":"10.1523\/JNEUROSCI.3360-13.2013","volume":"33","author":"D Balasuriya","year":"2013","unstructured":"Balasuriya D, Stewart AP, Edwardson JM. The \u03c3-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1\/GluN2A NMDA receptor. J Neurosci. 2013;33(46):18219\u201324. https:\/\/doi.org\/10.1523\/JNEUROSCI.3360-13.2013.","journal-title":"J Neurosci"},{"issue":"10","key":"852_CR129","doi-asserted-by":"publisher","first-page":"e76941","DOI":"10.1371\/journal.pone.0076941","volume":"8","author":"T Mori","year":"2013","unstructured":"Mori T, Hayashi T, Hayashi E, Su TP. Sigma-1 Receptor Chaperone at the ER-Mitochondrion Interface Mediates the Mitochondrion-ER-Nucleus Signaling for Cellular Survival. PLoS ONE. 2013;8(10):e76941. https:\/\/doi.org\/10.1371\/journal.pone.0076941.","journal-title":"PLoS ONE"},{"key":"852_CR130","doi-asserted-by":"publisher","first-page":"22468","DOI":"10.1073\/pnas.0909089106","volume":"106","author":"SY Tsai","year":"2009","unstructured":"Tsai SY, Hayashi T, Harvey BK, Wang Y, Wu WW, Shen RF, et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc Natl Acad Sci USA. 2009;106:22468\u201373. https:\/\/doi.org\/10.1073\/pnas.0909089106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"852_CR131","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/S0022-3565(24)35369-8","volume":"292","author":"BJ Vilner","year":"2000","unstructured":"Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther. 2000;292(3):900\u201311.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"852_CR132","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0014-2999(93)90940-j","volume":"241","author":"AP Jeanjean","year":"1993","unstructured":"Jeanjean AP, Mestre M, Maloteaux JM, Laduron PM. Is the sigma 2 receptor in rat brain related to the K+ channel of class III antiarrhythmic drugs? Eur J Pharmacol. 1993;241(1):111\u20136. https:\/\/doi.org\/10.1016\/0014-2999(93)90940-j.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"852_CR133","doi-asserted-by":"publisher","first-page":"e201900540","DOI":"10.26508\/lsa.201900540","volume":"4","author":"H Shen","year":"2020","unstructured":"Shen H, Li J, Xie X, Yang H, Zhang M, Wang B, et al. BRD2 regulation of sigma-2 receptor upon cholesterol deprivation. Life Sci Alliance. 2020;4(1):e201900540. https:\/\/doi.org\/10.26508\/lsa.201900540.","journal-title":"Life Sci Alliance"},{"key":"852_CR134","unstructured":"American Psychiatric Association. 2022. Depressive disorders. In Diagnostic and statistical manual of mental disorders (5th ed., text rev). https:\/\/cpcglobal.org\/publications\/DSM%205%20TR.pdf."},{"key":"852_CR135","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.neubiorev.2021.10.037","volume":"132","author":"K Salaciak","year":"2022","unstructured":"Salaciak K, Pytka K. Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders. Neurosci Biobeh Rev. 2022;132:1114\u201336. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.10.037.","journal-title":"Neurosci Biobeh Rev"},{"issue":"3","key":"852_CR136","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1254\/jphs.CRJ04005X","volume":"97","author":"JE Bermack","year":"2005","unstructured":"Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci. 2005;97(3):317\u201336.","journal-title":"J Pharmacol Sci"},{"key":"852_CR137","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3389\/fpsyt.2020.00381","volume":"11","author":"X Shao","year":"2020","unstructured":"Shao X, Zhu G. Associations Among Monoamine Neurotransmitter Pathways, Personality Traits, and Major Depressive Disorder. Front Psychiatry. 2020;11:381.","journal-title":"Front Psychiatry"},{"issue":"3","key":"852_CR138","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/sj.bjp.0704294","volume":"134","author":"JE Bermack","year":"2001","unstructured":"Bermack JE, Debonnel G. Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Br J Pharmacol. 2001;134(3):691\u20139.","journal-title":"Br J Pharmacol"},{"key":"852_CR139","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejphar.2017.05.035","volume":"809","author":"Y Ago","year":"2017","unstructured":"Ago Y, Hasebe S, Hiramatsu N, Hashimoto H, Takuma K, Matsuda T. Psychopharmacology of combined activation of the serotonin1A and \u03c31 receptors. Eur J Pharmacol. 2017;809:172\u20137. https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.035.","journal-title":"Eur J Pharmacol"},{"key":"852_CR140","doi-asserted-by":"publisher","first-page":"925879","DOI":"10.3389\/fphar.2022.925879","volume":"13","author":"P Ren","year":"2022","unstructured":"Ren P, Wang J, Li N, Li G, Ma H, Zhao Y, et al. Sigma-1 Receptors in Depression: Mechanism and Therapeutic Development. Front Pharmacol. 2022;13:925879. https:\/\/doi.org\/10.3389\/fphar.2022.925879.","journal-title":"Front Pharmacol"},{"issue":"1","key":"852_CR141","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1017\/neu.2017.8","volume":"30","author":"AJM Loonen","year":"2018","unstructured":"Loonen AJM, Ivanova SA. Circuits regulating pleasure and happiness: evolution and role in mental disorders. Acta Neuropsychiatrica. 2018;30(1):29\u201342. https:\/\/doi.org\/10.1017\/neu.2017.8.","journal-title":"Acta Neuropsychiatrica"},{"key":"852_CR142","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1017\/neu.2022.15","volume":"34","author":"AJM Loonen","year":"2022","unstructured":"Loonen AJM, Ivanova SA. Circuits regulating pleasure and happiness \u2013 focus on potential biomarkers for circuitry including the habenuloid complex. Acta Neuropsychiatrica. 2022;34:229\u201339. https:\/\/doi.org\/10.1017\/neu.2022.15.","journal-title":"Acta Neuropsychiatrica"},{"issue":"3\u20134","key":"852_CR143","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s0891-0618(00)00106-x","volume":"20","author":"K Kitaichi","year":"2000","unstructured":"Kitaichi K, Chabot JG, Moebius FF, Flandorfer A, Glossmann H, Quirion R. Expression of the purported sigma(1) (sigma(1)) receptor in the mammalian brain and its possible relevance in deficits induced by antagonism of the NMDA receptor complex as revealed using an antisense strategy. J Chem Neuroanat. 2000;20(3\u20134):375\u201387. https:\/\/doi.org\/10.1016\/s0891-0618(00)00106-x.","journal-title":"J Chem Neuroanat"},{"issue":"5","key":"852_CR144","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/ijnp\/pyaa089","volume":"24","author":"AM Rivas-Grajales","year":"2021","unstructured":"Rivas-Grajales AM, Salas R, Robinson ME, Qi K, Murrough JW, Mathew SJ. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2021;24(5):383\u201391. https:\/\/doi.org\/10.1093\/ijnp\/pyaa089.","journal-title":"Int J Neuropsychopharmacol"},{"key":"852_CR145","doi-asserted-by":"publisher","first-page":"705575","DOI":"10.3389\/fphys.2021.705575","volume":"12","author":"R Aishwarya","year":"2021","unstructured":"Aishwarya R, Abdullah CS, Morshed M, Remex NS, Bhuiyan MS, Sigma. R 1\u2019s Molecular, Cellular, and Biological Functions in Regulating Cellular Pathophysiology. Front Physiol. 2021;12:705575. https:\/\/doi.org\/10.3389\/fphys.2021.705575.","journal-title":"Front Physiol"},{"key":"852_CR146","doi-asserted-by":"publisher","first-page":"11325","DOI":"10.1523\/JNEUROSCI.0458-14.2014","volume":"34","author":"M Pabba","year":"2024","unstructured":"Pabba M, Wong AYC, Ahlskog N, Hristova E, Biscaro D, Nassrallah W, et al. NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus. J Neurosci. 2024;34:11325\u201338. https:\/\/doi.org\/10.1523\/JNEUROSCI.0458-14.2014.","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"852_CR147","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.neulet.2004.09.035","volume":"30372","author":"S Nudmamud-Thanoi","year":"2004","unstructured":"Nudmamud-Thanoi S, Reynolds GP. The NR1 subunit of the glutamate\/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett. 2004;30372(1\u20132):173\u20137.","journal-title":"Neurosci Lett"},{"issue":"3","key":"852_CR148","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1124\/jpet.107.124685","volume":"322","author":"D Wang","year":"2007","unstructured":"Wang D, Noda Y, Tsunekawa H, Zhou Y, Miyazaki M, Senzaki K, et al. Role of N-methyl-Daspartate Receptors in Antidepressant-Like Effects of 1 Receptor Agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine Dihydrochloride (SA-4503) in Olfactory Bulbectomized Rats. J Pharmacol Exp Ther. 2007;322(3):1305\u201314.","journal-title":"J Pharmacol Exp Ther"},{"key":"852_CR149","doi-asserted-by":"publisher","unstructured":"Iosifescu DV, Jones A, O\u2019Gorman C, Streicher C, Feliz S, Fava M, et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry. 2022;83(4):21m14345. https:\/\/doi.org\/10.4088\/JCP.21m14345. NCT04019704. A Trial of AXS-05 in Patients With Major Depressive Disorder (GEMINI), 2019.","DOI":"10.4088\/JCP.21m14345"},{"issue":"22","key":"852_CR150","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2020.22760","volume":"8","author":"EJ Lenze","year":"2020","unstructured":"Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19. A randomized clinical trial. JAMA. 2020;8(22):2292\u2013300.","journal-title":"JAMA"},{"key":"852_CR151","unstructured":"NCT04668950. Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)."},{"issue":"8","key":"852_CR152","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.biopsych.2008.05.014","volume":"64","author":"D Ong\u00fcr","year":"2008","unstructured":"Ong\u00fcr D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, et al. Abnormal glutamatergic neurotransmission, and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008;64(8):718\u201326. https:\/\/doi.org\/10.1016\/j.biopsych.2008.05.014.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"852_CR153","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0006-3223(91)90209-5","volume":"29","author":"AD Weissman","year":"1991","unstructured":"Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry. 1991;29(1):41\u201354.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"852_CR154","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/BF00966825","volume":"17","author":"H Shibuya","year":"1992","unstructured":"Shibuya H, Mori H, Toru M. Sigma receptors in schizophrenic cerebral cortices. Neurochem Res. 1992;17(10):983\u201390.","journal-title":"Neurochem Res"},{"issue":"1","key":"852_CR155","first-page":"47","volume":"1","author":"M Pabba","year":"2015","unstructured":"Pabba M, Sibille E. Sigma-1, and N-Methyl-d-Aspartate Receptors: A Partnership with Beneficial Outcomes. Mol Neuropsychiatry. 2015;1(1):47\u201351.","journal-title":"Mol Neuropsychiatry"},{"issue":"3","key":"852_CR156","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0920-9964(94)90035-3","volume":"12","author":"K Akiyama","year":"1994","unstructured":"Akiyama K, Kanzaki A, Tsuchida K, Ujike H. Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia. Schizophr Res. 1994;12(3):251\u20137.","journal-title":"Schizophr Res"},{"issue":"1","key":"852_CR157","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0304-3940(00)01258-1","volume":"28","author":"S Takahashi","year":"2000","unstructured":"Takahashi S, Miwa T, Horikomi K. Involvement of sgma1 receptors in methamphetamine-induced behavioral sensitization in rats. Neurosci Lett. 2000;28(1):21\u20134.","journal-title":"Neurosci Lett"},{"issue":"4","key":"852_CR158","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/157015905774322516","volume":"3","author":"T Hayashi","year":"2005","unstructured":"Hayashi T, Su TP. The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology. Curr Neuropharmacol. 2005;3(4):267\u201380.","journal-title":"Curr Neuropharmacol"},{"key":"852_CR159","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1744-859X-9-23","volume":"9","author":"A Kishimoto","year":"2010","unstructured":"Kishimoto A, Todani A, Miura J, Kitagaki T, Hashimoto K. The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report. Ann Gen Psychiatry. 2010;9:23. https:\/\/doi.org\/10.1186\/1744-859X-9-23.","journal-title":"Ann Gen Psychiatry"},{"key":"852_CR160","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0022-3565(24)35354-6","volume":"292","author":"CJ Kotzer","year":"2000","unstructured":"Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC. The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000;292:803\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"852_CR161","unstructured":"NCT06574360. Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia, 2024."},{"issue":"9","key":"852_CR162","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3390\/brainsci14090881","volume":"14","author":"K Tarmoun","year":"2024","unstructured":"Tarmoun K, Lachance V, Le Corvec V, B\u00e9langer SM, Beaucaire G, Kourrich S. Comprehensive Analysis of Age- and Sex-Related Expression of the Chaperone Protein Sigma-1R in the Mouse Brain. Brain Sci. 2024;14(9):881. https:\/\/doi.org\/10.3390\/brainsci14090881.","journal-title":"Brain Sci"},{"key":"852_CR163","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2018.01.009","volume":"186","author":"DO Sambo","year":"2018","unstructured":"Sambo DO, Lebowitz JJ, Khoshbouei H. The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction. Pharmacol Ther. 2018;186:152\u201367. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.009.","journal-title":"Pharmacol Ther"},{"key":"852_CR164","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.neubiorev.2018.06.018","volume":"106","author":"V Mathis","year":"2019","unstructured":"Mathis V, Kenny PJ. From controlled to compulsive drug-taking: The role of the habenula in addiction. Neurosci Biobehav Rev. 2019;106:102\u201311. https:\/\/doi.org\/10.1016\/j.neubiorev.2018.06.018.","journal-title":"Neurosci Biobehav Rev"},{"key":"852_CR165","doi-asserted-by":"publisher","first-page":"1455622","DOI":"10.3389\/fnbeh.2024.1455622","volume":"18","author":"SY Seo","year":"2024","unstructured":"Seo SY, Bang SK, Kang SY, Cho SJ, Choi K-H, Ryu Y. Mechanical acupuncture at HT7 attenuates alcohol self-administration in rats by modulating neuroinflammation and altering mPFC-habenula-VTA circuit activity. Front Beh Neurosci. 2024;18:1455622. https:\/\/doi.org\/10.3389\/fnbeh.2024.1455622.","journal-title":"Front Beh Neurosci"},{"issue":"3","key":"852_CR166","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1055\/s-2004-832678","volume":"37","author":"T Maurice","year":"2004","unstructured":"Maurice T, Romieu P. Involvement of the sigma1 receptor in the appetitive effects on cocaine. Pharmacopsychiatry. 2004;37(3):198\u2013207.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"852_CR167","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00213-004-1779-9","volume":"175","author":"R Stefanski","year":"2004","unstructured":"Stefanski R, Justinova Z, Hayashi T, Takebayashi M, Goldberg SR, Su TP. Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls. Psychopharmacol (Berl. 2004;175(1):68\u201375.","journal-title":"Psychopharmacol (Berl"},{"key":"852_CR168","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bbr.2015.10.013","volume":"297","author":"M Valenza","year":"2016","unstructured":"Valenza M, DiLeo A, Steardo L, Cottone P, Sabino V. Ethanol-related behaviors in mice lacking the sigma-1 receptor. Behav Brain Res. 2016;297:196\u2013203. https:\/\/doi.org\/10.1016\/j.bbr.2015.10.013.","journal-title":"Behav Brain Res"},{"key":"852_CR169","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3389\/fphar.2019.00687","volume":"10","author":"SG Quadir","year":"2019","unstructured":"Quadir SG, Cottone P, Sabino V. Role of Sigma Receptors in Alcohol Addiction. Front Pharmacol. 2019;10:687. https:\/\/doi.org\/10.3389\/fphar.2019.00687.","journal-title":"Front Pharmacol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00852-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:03:12Z","timestamp":1781686992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00852-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":169,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00852-8","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The work did not involve directly the animals and human subjects and did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}